Intronic GGGGCC (G4C2) hexanucleotide repeat expansion within the human C9orf72 gene represents the most common cause of familial forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (C9ALS/FTD). Repeat-associated non-AUG (RAN) translation of repeat-containing C9orf72 RNA results in the production of neurotoxic dipeptide-repeat proteins (DPRs). Here, we developed a high-throughput drug screen for the identification of positive and negative modulators of DPR levels. We found that HSP90 inhibitor geldanamycin and aldosterone antagonist spironolactone reduced DPR levels by promoting protein degradation via the proteasome and autophagy pathways respectively. Surprisingly, cAMP-elevating compounds boosting protein kinase A (PKA) activity increased DPR levels. Inhibition of PKA activity, by both pharmacological and genetic approaches, reduced DPR levels in cells and rescued pathological phenotypes in a Drosophila model of C9ALS/FTD. Moreover, knockdown of PKA-catalytic subunits correlated with reduced translation efficiency of DPRs, while the PKA inhibitor H89 reduced endogenous DPR levels in C9ALS/FTD patient-derived iPSC motor neurons. Together, our results suggest new and druggable pathways modulating DPR levels in C9ALS/FTD.

C9orf72 ALS/FTD dipeptide repeat protein levels are reduced by small molecules that inhibit PKA or enhance protein degradation / N.V. Licata, R. Cristofani, S. Salomonsson, K.M. Wilson, L. Kempthorne, D. Vaizoglu, V.G. D’Agostino, D. Pollini, R. Loffredo, M. Pancher, V. Adami, P. Bellosta, A. Ratti, G. Viero, A. Quattrone, A.M. Isaacs, A. Poletti, A. Provenzani. - In: EMBO JOURNAL. - ISSN 0261-4189. - (2021), pp. e105026.1-e105026.23. [Epub ahead of print] [10.15252/embj.2020105026]

C9orf72 ALS/FTD dipeptide repeat protein levels are reduced by small molecules that inhibit PKA or enhance protein degradation

R. Cristofani
Co-primo
;
P. Bellosta;A. Ratti;A. Poletti
Penultimo
;
2021

Abstract

Intronic GGGGCC (G4C2) hexanucleotide repeat expansion within the human C9orf72 gene represents the most common cause of familial forms of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) (C9ALS/FTD). Repeat-associated non-AUG (RAN) translation of repeat-containing C9orf72 RNA results in the production of neurotoxic dipeptide-repeat proteins (DPRs). Here, we developed a high-throughput drug screen for the identification of positive and negative modulators of DPR levels. We found that HSP90 inhibitor geldanamycin and aldosterone antagonist spironolactone reduced DPR levels by promoting protein degradation via the proteasome and autophagy pathways respectively. Surprisingly, cAMP-elevating compounds boosting protein kinase A (PKA) activity increased DPR levels. Inhibition of PKA activity, by both pharmacological and genetic approaches, reduced DPR levels in cells and rescued pathological phenotypes in a Drosophila model of C9ALS/FTD. Moreover, knockdown of PKA-catalytic subunits correlated with reduced translation efficiency of DPRs, while the PKA inhibitor H89 reduced endogenous DPR levels in C9ALS/FTD patient-derived iPSC motor neurons. Together, our results suggest new and druggable pathways modulating DPR levels in C9ALS/FTD.
Motor neuron disease; C9ORF72; RAN translation; protein kinase A; Amyotrophic lateral sclerosis
Settore BIO/13 - Biologia Applicata
Settore MED/03 - Genetica Medica
   Alternative translation initiation as a novel strategy to block toxicity of the mutant Androgen Receptor in SBMA
   FONDAZIONE TELETHON ETS
   GGP19128

   RAN translation of normal and expanded nucleotide repeat containing transcripts to neurotoxic polypetides in neurodegenerative diseases
   No RAn for old man
   FONDAZIONE CARIPLO
   2014-0686

   Targeting RAN translation in ALS (Target-RAN)
   Target-RAN
   FONDAZIONE ITALIANA DI RICERCA PER LA SLA - SCLEROSI LATERALE AMIOTROFICA - ARISLA

   Membrane-less organelle pathology in ALS: identification of causes and rescuing factors (MLOMALS)
   MLOMALS
   FONDAZIONE ITALIANA DI RICERCA PER LA SLA - SCLEROSI LATERALE AMIOTROFICA - ARISLA

   Selective translation of androgen receptor isoform A to prevent polyQ mediated toxicity in Kennedy’s disease
   KENNEDY'S DISEASE ASSOCIATION

   Colchicine for Amyotrophic Lateral Sclerosis: a phase II, randomized, double blind, placebo controlled, multicenter clinical trial (Co-ALS)
   Co-ALS
   AGENZIA ITALIANA DEL FARMACO - AIFA
   AIFA-2016-02364678

   Translating molecular mechanisms into ALS risk and patient's well-being
   TRANS-ALS
   FONDAZIONE REGIONALE PER LA RICERCA BIOMEDICA
   2015-0023

   The interplay between the “rna/protein quality control system” and “exosomes” as a spreading mechanism in amyotrophic lateral sclerosis (EX_ALS)
   EX_ALS
   MINISTERO DELL'ISTRUZIONE E DEL MERITO
   2017F2A2C5_001
2021
18-nov-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
embj.2020105026.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 5.11 MB
Formato Adobe PDF
5.11 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/883991
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 13
social impact